| ABSSSI
Dalvance vs Sivextro
Side-by-side clinical, coverage, and cost comparison for absssi.Deep comparison between: Dalvance vs Sivextro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSivextro has a higher rate of injection site reactions vs Dalvance based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sivextro but not Dalvance, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Dalvance
Sivextro
At A Glance
IV infusion
Single or two-dose (1 week apart)
Lipoglycopeptide antibacterial
Oral or IV infusion
Once daily
Oxazolidinone antibacterial
Indications
- ABSSSI
- ABSSSI
Dosing
ABSSSI Adults with CLcr >=30 mL/min: 1,500 mg single IV dose or 1,000 mg followed one week later by 500 mg, infused over 30 minutes; adults with CLcr <30 mL/min not on hemodialysis: 1,125 mg single dose or 750 mg followed one week later by 375 mg; pediatric patients (CLcr >=30 mL/min/1.73m2): 22.5 mg/kg (max 1,500 mg) for birth to <6 years, or 18 mg/kg (max 1,500 mg) for 6 to <18 years, as a single IV dose.
ABSSSI 200 mg once daily orally (with or without food) or as an IV infusion over 1 hour for 6 days in patients 12 years of age and older.
Contraindications
- Known hypersensitivity to dalbavancin
—
Adverse Reactions
Most common (>=2%) nausea, headache, diarrhea, vomiting, rash, pruritus
Serious hypersensitivity reactions, infusion-related reactions, hepatic effects, Clostridioides difficile-associated diarrhea
Postmarketing back pain as an infusion-related reaction
Most common (>=2%) nausea, headache, diarrhea, infusion- or injection-related adverse reactions, vomiting, dizziness
Serious myelosuppression, peripheral neuropathy, optic neuropathy
Postmarketing thrombocytopenia
Pharmacology
Dalbavancin is a semisynthetic lipoglycopeptide antibacterial that interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, preventing cross-linking; it is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes at concentrations sustained throughout treatment.
Tedizolid is an oxazolidinone-class antibacterial that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit; it is bacteriostatic against staphylococci, streptococci, and enterococci.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Dalvance
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Sivextro
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Dalvance
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Sivextro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Dalvance
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Sivextro
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Skin & Skin Structure Infections: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Sivextro.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DalvanceView full Dalvance profile
SivextroView full Sivextro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.